AC
ARNA

AlphaCore Capital’s Arena Pharmaceuticals Inc ARNA Stock Holding History

AlphaCore Capital’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-50
Closed -$2K – 331
2020
Q1 		$2K Buy
+50
New +$2.29K ﹤0.01% 310

Other funds holding ARNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AlphaCore Capital's ARNA Position: Q2 2020 in Review

AlphaCore Capital sold out of Arena Pharmaceuticals Inc (ARNA) in Q2 2020, closing a stake of 50 shares — an estimated $2K sold.

AlphaCore Capital first reported a position in ARNA in Q1 2020 and held it in 1 quarter. The position peaked at $2K in Q1 2020. 247 funds tracked by Wall St. Rank hold ARNA as of Q2 2020.

  • AlphaCore Capital reported no remaining Arena Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • AlphaCore Capital sold 50 Arena Pharmaceuticals Inc shares in Q2 2020, an estimated $2K.
  • AlphaCore Capital first reported a position in Arena Pharmaceuticals Inc in Q1 2020 and held it in 1 quarter.
  • AlphaCore Capital's Arena Pharmaceuticals Inc position peaked at $2K in Q1 2020.
  • 247 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q2 2020.

Based on AlphaCore Capital's 13F filing for Q2 2020, filed 14 Aug 2020.